Download PDF
Semin Liver Dis 2000; Volume 20(Number 01): 0017-0036
DOI: 10.1055/s-2000-9505
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4663

Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome

Harvey J. Alter, Leonard B. Seeff
  • Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, and Section of Digestive Diseases and Nutrition, NIDDK, NIH, Bethesda, Maryland
Further Information

Publication History

Publication Date:
31 December 2000 (online)

    Permissions and Reprints

ABSTRACT

Hepatitis C has emerged in recent years as the most common basis for liver disease in the United States, having infected an estimated 3.9 million people in this country and an estimated 170 million worldwide. Currently, it is the predominant reason for undergoing liver transplantation. The disease it causes is characterized by silent onset in most infected individuals, a high rate of viral persistence, and the potential for development of ever-worsening chronic liver disease, ranging from chronic hepatitis to cirrhosis and occasionally to hepatocellular carcinoma. Such progression, when it occurs, is also most commonly a silent process that may take 20-40, and occasionally even more, years to reach its end point. Because of these characteristics, it has been exceedingly difficult to accurately assess the natural history. Efforts to accomplish this have consisted of retrospective, prospective, and cohort studies. The most concerning data have derived from the retrospective study approach, generally performed at tertiary referral centers. Because these centers commonly attract persons with existing chronic liver disease, they have tended to describe a high rate of progression to cirrhosis and cancer. This ``referral bias'' is avoided in the prospective and cohort study approach, and data derived from these studies indicate a lower rate of progression and a correspondingly higher rate of either recovery or minimal liver disease. In this review, we briefly describe potential mechanisms of viral persistence; present detailed information on outcomes that have derived from retrospective, prospective, and cohort studies, involving both adults and children; examine the data regarding progression of fibrosis and of progression to hepatocellular carcinoma; consider cofactors that might enhance liver disease progression; and report the emerging data that suggest that spontaneous viral clearance may be higher than is currently believed. We conclude with the view that severe, life-threatening, progressive liver disease clearly occurs in a sizable minority (perhaps 30%) of chronically infected persons but speculate that fibrosis progression is neither linear or inevitable and hence that most hepatitis C virus carriers will have either a stable nonprogressive course or such indolent progression that they will die from an unrelated disease before the severe sequelae of hepatitis C become manifest or will have a sustained ``curative'' response to therapy. Although this view provides reasonable hope to the hepatitis C virus-infected individual, it does not deny the enormous burden this infection presents as the result of its high prevalence and global distribution. The sheer magnitude of the infected population will result in a large number with severe life-threatening liver disease even if the proportion of infected individuals that develop progressive disease is relatively small.

KEYWORD

HCV - chronic hepatitis - fibrosis - cirrhosis

REFERENCES

  • 1 Dienstag J L. Non-A, non-B hepatitis. I. Recognition, epidemiology and clinical features.  Gastroenterology . 1983;  85 439-462
    PubMedSearch in Google Scholar
  • 2 Seeff L B. Hepatitis C from a needlestick injury.  Ann Intern Med . 1991;  115 411
    PubMedSearch in Google Scholar
  • 3 Alter H J, Purcell R H, Holland P V, Popper H. Transmissible agent in non-A, non-B hepatitis.  Lancet . 1978;  1 459-463
    CrossrefPubMedSearch in Google Scholar
  • 4 Tabor E, Gerety R J, Drucker J A. Transmission of non-A, non-B hepatitis from man to chimpanzee.  Lancet . 1978;  1 463-466
    PubMedSearch in Google Scholar
  • 5 Tabor E, Purcell R H, Gerety R J. Primate animal models and titered inocula for the study of human hepatitis A, B, and non-A, non-B hepatitis.  J Med Primatol . 1981;  1 305-318
    PubMedSearch in Google Scholar
  • 6 Choo Q-L, Kuo G, Weiner A J, Overby L R, Bradley D W, Houghton M. Isolation of cDNA clone derived from blood-borne non-A, non-B viral hepatitis genome.  Science . 1989;  244 359-362
    CrossrefPubMedSearch in Google Scholar
  • 7 Alter H J. Chronic consequences of non-A, non-B hepatitis. In: Seeff LB, Lewis JH, eds. Hepatology: Festschrift for Hyman J Zimmerman, M.D. New York: Plenum Press 1989: 83-97
    Search in Google Scholar
  • 8 Gilliam III H J, Geisinger K R, Richter J E. Primary hepatocellular carcinoma after chronic non-A, non-B post-transfusion hepatitis.  Ann Intern Med . 1984;  101 794
    PubMedSearch in Google Scholar
  • 9 Kiyosawa K, Sodeyama T, Tanaka E. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus.  Hepatology. 1990;  12 671-675
    PubMedSearch in Google Scholar
  • 10 Tong M J, El-Farra N S, Reikes A R, Co R L. Clinical outcomes after transfusion-associated hepatitis C.  N Engl J Med . 1995;  332 1463-1466
    CrossrefPubMedSearch in Google Scholar
  • 11 Bruix J, Barrera J M, Calvet X. Prevalence of antibody to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis.  Lancet . 1989;  2 1004-1006
    PubMedSearch in Google Scholar
  • 12 Colombo M, Kuo G, Choo Q L. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma.  Lancet . 1989;  2 1006-1008
    PubMedSearch in Google Scholar
  • 13 Alter H J, Conry-Cantilena C, Melpolder J, Tan D, Van Raden M, Herion D, Lau D, Hoofnagle J H. Hepatitis C in asymptomatic blood donors.  Hepatology . 1997;  26(Suppl 1) 29S-33S
    CrossrefPubMedSearch in Google Scholar
  • 14 Alter M J, Margolis H S, Krawczynski K. The natural history of community-acquired hepatitis C in the United States.  N Engl J Med . 1992;  327 1899-1905
    CrossrefPubMedSearch in Google Scholar
  • 15 Alter M J, Kruszon-Moran D, Nainan O V, McQuillan G M, Gao F, Moyer L A, Kaslow R A, Margolis H S. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.  N Engl J Med . 1999;  341 556-562
    CrossrefPubMedSearch in Google Scholar
  • 16 Pessoa M G, Wright T L. Hepatitis C infection in transplantation.  Clin Liver Dis . 1997;  1 663-690
    PubMedSearch in Google Scholar
  • 17 Farci P, Alter H J, Govindarajan S. Lack of protective immunity against reinfection with hepatitis C virus.  Science . 1992;  258 135-140
    CrossrefPubMedSearch in Google Scholar
  • 18 Shimizu Y K, Yoshikuta H, Hijikata M, Iwamoto A, Alter H J, Purcell RH.Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutants. J Virol .  1994;  68 1494-1500
    PubMedSearch in Google Scholar
  • 19 Rosa D, Campagnoli S, Moretto C. A quantitative test to estimate neutralizing antibodies to the hepatitis c virus: Cytofluorometric assessment of envelop glycoprotein 2 binding to target cells.  Proc Natl Acad Sci USA . 1996;  93 1759-1763
    CrossrefPubMedSearch in Google Scholar
  • 20 Farci P, Shimoda A, Coiana A. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies.  Proc Natl Acad Sci USA (in press) .
    PubMed
  • 20a Bukh J, Yanagi M, Emerson S U, Purcell R H. Course of infection and evolution of monoclonal hepatitis C virus (HCV) strain H77 in chimpanzees transfected with RNA transcripts from an infectious cDNA clone.  Hepatology . 1998;  28 319A
    PubMedSearch in Google Scholar
  • 21 Cerny A, Chisari F V. Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence.  Hepatology . 1999;  30 595-601
    CrossrefPubMedSearch in Google Scholar
  • 22 Lai M E, Mazzoleni A P, Argiolu F, De Virgilis S, Balastrieri A, Purcell R H, Farci P. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children.  Lancet . 1994;  343 388-390
    CrossrefPubMedSearch in Google Scholar
  • 23 Weiner A, Erickson A L, Kansopon J. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant.  Proc Natl Acad Sci USA . 1995;  92 2755-2759
    PubMedSearch in Google Scholar
  • 24 Eyster M E, Diamondstone L S, Lien J M. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study.  J Acquir Immune Def Syndr . 1993;  6 602-610
    PubMedSearch in Google Scholar
  • 25 Yano M, Kumada H, Kage M. The long-term pathological evolution of chronic hepatitis C.  Hepatology . 1996;  23 1334-1340
    CrossrefPubMedSearch in Google Scholar
  • 26 Niederau C, Lange S, Heintges T. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study.  Hepatology . 1998;  28 1687-1695
    CrossrefPubMedSearch in Google Scholar
  • 27 Di Bisceglie M A, Goodman Z D, Ishak K G, Hoofnagle J H, Melpolder J J, Alter H J. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis.  Hepatology . 1991;  14 969-974
    CrossrefPubMedSearch in Google Scholar
  • 28 Koretz R L, Abbey H, Cloeman E, Gitnick G. Non-A, non-B post-transfusion hepatitis: Looking back in the second decade.  Ann Intern Med . 1993;  119 110-115
    PubMedSearch in Google Scholar
  • 29 Mattson L, Sonnerborg A, Weiland O. Outcome of acute asymptomatic non-A, non-B hepatitis: A 13-year follow-up study of hepatitis C virus markers.  Liver . 1993;  13 274-278
    PubMedSearch in Google Scholar
  • 30 Tremolada F, Casarin C, Albert A, Drago C, Tagger A, Ribero M L, Realdi G. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis.  J Hepatol . 1992;  16 273-281
    CrossrefPubMedSearch in Google Scholar
  • 31 Alter H J, Purcell R H, Feinstone S M, Holland P V, Morrow A G. Non-A/non-B hepatitis: A review and interim report of an ongoing prospective study. In: Vyas GN, Cohen SN, Schmid R, eds. Viral Hepatitis: A Contemporary Assessment of Etiology, Epidemiology, Pathogenesis and Prevention Philadelphia: Franklin Institute Press 1978: 359-369
    Search in Google Scholar
  • 32 Seeff L B, Buskell-Bales Z, Wright E C. Long-term mortality after transfusion-associated non-A, non-B hepatitis.  N Engl J Med. 1992;  327 1906-1911
    CrossrefPubMedSearch in Google Scholar
  • 33 Seeff L B, Zimmerman H J, Wright E C. A randomized, double-blind, controlled trial of the efficacy of immune serum globulin in the prevention of post-transfusion hepatitis: A Veterans Administration cooperative study.  Gastroenterology. 1977;  72 111-121
    PubMedSearch in Google Scholar
  • 34 Seeff L B, Wright E C, Zimmerman H J. Posttransfusion hepatitis, 1973-1975; A Veterans Administration cooperative study. In: Vyas GN, Cohen SN, Schmid R, eds. Viral Hepatitis: A Contemporary Assessment of Etiology, Epidemiology, Pathogenesis and Prevention Philadelphia: Franklin Institute Press 1978: 371-381
    Search in Google Scholar
  • 35 Aach R D, Szmuness W, Mosley J W. Serum alanine aminotransferase of donors in relation to risk of non-A, non-B hepatitis in recipients: The Transfusion-Transmitted Viruses Study.  N Engl J Med . 1981;  304 989-994
    CrossrefPubMedSearch in Google Scholar
  • 36 Knodell R G, Conrad M E, Ginsberg A L, Bell C J, Flanery E P. Efficacy of prophylactic gamma-globulin in preventing non-A, non-B hepatitis.  Lancet. 1976;  1 557-561
    PubMedSearch in Google Scholar
  • 37 Wright E C, Seeff L B, Hollinger F B, Alter H J, Buskell-Bales Z, Cain C, the NHLBI Study Group. Updated long-term mortality of transfusion- associated hepatitis (TAH), non-A, non-B and C.  Hepatology . 1998;  28 272A
    CrossrefPubMedSearch in Google Scholar
  • 38 Seeff L B, Hollinger F B, Alter H J, Wright E C, Bales Z B, the NHLBI Study Group. Long-term morbidity of transfusion-associated hepatitis (TAH) C.  Hepatology . 1998;  28 407A
    PubMedSearch in Google Scholar
  • 39 Denny F W, Wannamaker L W, Brink W R, Rammelkamp H. Prevention of rheumatic fever, treatment of preceding streptococcic infection.  JAMA . 1950;  143 151-153
    PubMedSearch in Google Scholar
  • 40 Seeff L B, Miller R N, Rabkin C S, Bales Z B, Smoak B L, Johnson L D, Kaplan E L. 45-Year follow-up of hepatitis C virus infection in healthy young adults.  Ann Intern Med . 2000;  132 105-111
    PubMedSearch in Google Scholar
  • 41 Conry-Cantilena C, VanRaden M, Gibble J. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection.  N Engl J Med . 1996;  334 1691-1696
    CrossrefPubMedSearch in Google Scholar
  • 42 Shakil A O, Conry-Cantilena C, Alter H J. Volunteer blood donors with antibody to hepatitis C virus: Clinical, biochemical, virologic and histologic features.  Ann Intern Med . 1995;  123 330-337
    PubMedSearch in Google Scholar
  • 43 Kenny-Walsh E for the Irish Hepatology Research Group. Clinical outcomes after hepatitis infection from contaminated anti-globulin.  N Engl J Med . 1999;  340 1228-1233
    CrossrefPubMedSearch in Google Scholar
  • 44 Muller R. The natural history of hepatitis C: Clinical experiences.  J Hepatol . 1996;  24(Suppl) 52-54
    CrossrefPubMedSearch in Google Scholar
  • 45 Vogt M, Lang T, Frosner G. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening.  N Engl J Med . 1999;  341 866-870
    CrossrefPubMedSearch in Google Scholar
  • 46 Locasciulli A, Testa M, Pontisso P. Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia.  Blood . 1997;  11 4628-4633
    PubMedSearch in Google Scholar
  • 47 Garcia-Monzon C, Jara P, Fernandez-Bermejo M. Chronic hepatitis C in children: A clinical and immunohistochemical comparative study with adults.  Hepatology . 1998;  28 1696-1701
    CrossrefPubMedSearch in Google Scholar
  • 48 Luban N, Post J, Glymph C. Transfusion associated hepatitis C and G in pediatric patients identified through a universal look-back approach.  Transfusion . 1999;  106(Suppl 1) 110S
    PubMedSearch in Google Scholar
  • 49 Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR,and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C.  Lancet . 1997;  349 825-832
    CrossrefPubMedSearch in Google Scholar
  • 50 Fattovich G, Giustina G, Degos F. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients.  Gastroenterology . 1997;  112 463-472
    CrossrefPubMedSearch in Google Scholar
  • 51 Serfaty L, Aumaitre H, Chazouilleres O, Bonand A-M, Rosmorduc O, Poupon R E, Poupon R. Determinants of outcome of compensated hepatitis C virus-related cirrhosis.  Hepatology . 1998;  27 1435-1440
    PubMedSearch in Google Scholar
  • 52 Nishioka K, Watanabe J, Furuta S. A high prevalence of the antibody to hepatitis C virus with hepatocellular carcinoma in Japan.  Cancer . 1991;  67 429-433
    PubMedSearch in Google Scholar
  • 53 Kato Y, Nakata K, Omagari K. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan: Analysis of infectious hepatitis viruses.  Cancer . 1994;  74 2234-2238
    PubMedSearch in Google Scholar
  • 54 Yoshida H, Shiratori Y, Moriyama M. Interferon therapy reduces the risk for hepatocellular carcinoma: National Surveillance Program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan.  Ann Int Med . 1999;  131 174-181
    PubMedSearch in Google Scholar
  • 55 Chen P-J, Chen D-S. Hepatitis B virus and hepatocellular carcinoma. In: Okuda K, Tabor E, eds. Liver Cancer New York: Churchill Livingstone 1997: 29-37
    Search in Google Scholar
  • 56 Hadziyannis S, Tabor E, Kaklamani E. A case-control study of hepatitis B and C virus infections in the etiology of hepatocellular carcinoma.  Int J Cancer. 1995;  60 627-631
    PubMedSearch in Google Scholar
  • 57 Kew M C, Houghton M, Choo Q L, Kuo G. Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma.  Lancet. 1990;  335 873-874
    CrossrefPubMedSearch in Google Scholar
  • 58 Yu M C, Tong M J, Coursaget P. Prevalence of hepatitis B and C markers in black and white patients with hepatocellular carcinoma in the United States.  J Natl Cancer Inst . 1990;  82 1038-1041
    PubMedSearch in Google Scholar
  • 59 Di Bisceglie M A, Order S E, Klein J L. The role of chronic viral hepatitis in hepatocellular carcinoma in the United States.  Am J Gastroenterol . 1991;  86 335-338
    PubMedSearch in Google Scholar
  • 60 Hassan F, Jeffers L J, Medina M. Hepatitis C-associated hepatocellular carcinoma.  Hepatology . 1990;  12 589-591
    PubMedSearch in Google Scholar
  • 61 Liang T J, Jeffers L J, Reddy K R. Viral pathogenesis of hepatocellular carcinoma on the United States.  Hepatology . 1993;  18 1326-1333
    CrossrefPubMedSearch in Google Scholar
  • 62 Gordon S C, Eloway R S, Long J C. The pathology of hepatitis C as a function of mode of transmission. Blood transfusion versus intravenous drug use.  Hepatology . 1993;  18 1338-1343
    CrossrefPubMedSearch in Google Scholar
  • 63 Pozatto G, Kaneko S, Moretti M. Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease.  J Med . 1994;  43 291
    PubMedSearch in Google Scholar
  • 64 Davis G L, Lau J YN. Factors predictive of a beneficial response to therapy of hepatitis C.  Hepatology . 1997;  26(Suppl 1) 122S
    CrossrefPubMedSearch in Google Scholar
  • 65 Gretch D, Corey L, Wilson J. Assessment of hepatitis C virus RNA levels by competetive RNA polymerase chain reaction: High titer viremia correlates with advanced stage of disease.  J Infect Dis . 1994;  169 1219-1225
    PubMedSearch in Google Scholar
  • 66 Bjorkander J, Cunningham-Runnels C, Lundin P, Olsson R, Soderstrom R, Hanson L A. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency.  Am J Med . 1988;  84 107-111
    CrossrefPubMedSearch in Google Scholar
  • 67 Bjoro K, Froland S S, Yun Z. Hepatitis C infection inpatients with primary hypogammmaglobulinemia after treatment with contaminated immune globulin.  N Engl J Med . 1994;  331 1607-1611
    CrossrefPubMedSearch in Google Scholar
  • 68 Tefler P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C. The progression of HCV-associated liver disease in a cohort of hemophilic patients.  Br J Haemotol . 1994;  87 555-561
    PubMedSearch in Google Scholar
  • 69 Markis M, Preston F E, Rosendaal F R, Underwood J CE, Rice K M, Triger D R. The natural history of chronic hepatits C in hemophiliacs.  Br J Haemotol . 1996;  94 746-752
    PubMedSearch in Google Scholar
  • 70 Darby S C, Ewart D W, Giangrande P L. Mortality from liver cancer and liver disease in hemophiliac men and boys in UK given blood products contaminated with hepatitis C.  Lancet . 1997;  350 1425-1431
    CrossrefPubMedSearch in Google Scholar
  • 71 Villano S A, Vlahov D, Nelson K E, Cohn S, Thomas D L. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection.  Hepatology . 1999;  29 908-914
    CrossrefPubMedSearch in Google Scholar
  • 72 Thursz M, Rhiannon Y, Goldin R, Trepo C, Thomas H C. Influence of MHC class II genotype on outcome of infection with hepatitis C virus.  Lancet . 1999;  354 2119-2124
    CrossrefPubMedSearch in Google Scholar
  • 73 Aikawa T, Kojima M, Onishi H. HLA DRB1 and DQB1 alleles and haplotypes influencing the progression of hepatitis C.  J Med Virol . 1996;  49 274-278
    CrossrefPubMedSearch in Google Scholar
  • 74 Bellentani S W, Pozzato G, Saccoccio G. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: Report from the Dionysos study.  Gut . 1999;  44 874-880
    CrossrefPubMedSearch in Google Scholar
  • 75 Corrao G, Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis.  Hepatology . 1998;  27 914-919
    CrossrefPubMedSearch in Google Scholar
  • 76 Ostapowicz G, Watson K SR, Locarnini A, Desmond P. Role of alcohol in the prognosis of liver disease caused by hepatitis C virus infection.  Hepatology . 1998;  27 1730-1735
    CrossrefPubMedSearch in Google Scholar
  • 77 Gomez M R, Nogales M C, Grande L. Alcohol consumption enhances intrahepatic hepatitis C virus replication.  Hepatology . 1998;  28 280A
    PubMedSearch in Google Scholar
  • 78 Wiley T E, McCarthy M, Breide L, McCarthy M, Layden T. Impact of alcohol on the histological and clinical progression of hepatitis C infection.  Hepatology . 1998;  28 805-809
    CrossrefPubMedSearch in Google Scholar
  • 79 McHutchison J G, Gorden S C, Schiff E R. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.  N Engl J Med . 1998;  339 1485-1492
    CrossrefPubMedSearch in Google Scholar